SMO protein inhibitors - Pipeline Insight, 2022

“SMO protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in SMO protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

SMO protein inhibitors Understanding

SMO protein inhibitors: Overview

SMO is a G-protein-coupled receptor (GPCR) of the Frizzled-class (class-F). It transduces the Hedgehog signal from the tumour suppressor Patched-1 (PTCH1) to the glioma-associated-oncogene (GLI) transcription factors, which activates the Hedgehog signalling pathway. Mutations in SMO that lead to constitutive activation of SMO are known to play a role in carcinogenesis of basal cell carcinoma, glioblastoma, medulloblastoma, and rhabdomyosarcoma. Overexpression of either Wnt-1 or the GLI proteins results in cancer. Inhibition of the Smoothened (SMO) protein prevents the induction of GLI transcriptional activity upon exposure of cancer cells to Shh ligands. Loss of induction of GLIs upon activation of Shh signaling inhibits the ability of Shh signaling to promote tumor progression. Therapies that inhibit Smo have many applications in cancer treatment, therefore several active clinical trials are going on to check efficacy.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence SMO protein inhibitors R&D. The therapies under development are focused on novel approaches for SMO protein inhibitors.

SMO protein inhibitors Emerging Drugs Chapters

This segment of the SMO protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

SMO protein inhibitors Emerging Drugs
• GT1708F: Suzhou Kintor Pharmaceuticals

GT 1708F is a smoothened trans-membrane protein (SMO) antagonist (or Hedgehog signaling pathway inhibitor). The drug is currently in Phase I clinical studies for the treatment of leukemia and Basal Cell Carcinoma.
• ENV-101: Endeavor BioMedicines

ENV-101 (taladegib) is a small-molecule inhibitor of the Hedgehog signaling pathway that is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). Endeavor intends to initiate a Phase 2 study of ENV-101 as a monotherapy in patients with IPF in the second quarter of 2021.

Further product details are provided in the report……..

SMO protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different SMO protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on SMO protein inhibitors

There are approx. 8+ key companies which are developing the SMO protein inhibitors. The companies which have their SMO protein inhibitors drug candidates in the most advanced stage, i.e. Phase III, PellePharm.
• Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

SMO protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

SMO protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses SMO protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging SMO protein inhibitors drugs.

SMO protein inhibitors Report Insights
• SMO protein inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

SMO protein inhibitors Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing SMO protein inhibitors drugs?
• How many SMO protein inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for SMO protein inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the SMO protein inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for SMO protein inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Pfizer
• Endeavor BioMedicines
• PellePharm
• Sun Pharmaceutical Industries
• Roche
• Guangdong Zhongsheng Pharmaceutical
• Suzhou Kintor Pharmaceuticals

Key Products
• Glasdegib
• ENV-101
• Patidegib
• Sonidegib
• Vismodegib
• ZSP1602
• GT1708F